China’s BeiGene Doses First Patient in BGB-A317’s Hodgkin Lymphoma Trial
News
China’s BeiGene says a Phase 2 clinical trial testing the company’s new PD-1 antibody, BGB-A317, in patients with relapsed or refractory classical Hodgkin lymphoma has dosed its first patient. Professor Jun Zhu of Peking University Cancer Hospital ... Read more